Company: BDRX
Filing Date: 2025-05-12
Form Type: 424B3
Source: 0001214659-25-007342
Chunk: 14

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-12
Form: 424B3
Chunk 14
---
 forward-looking statements
prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements,
you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and
plans in any specified timeframe, or at all.

| 12 |

<div align='center'>THE COMMITTED EQUITY FINANCING</div>

Overview

On January 17, 2025, we entered
into the Purchase Agreement with the Selling Shareholder. Sales of our Depositary Shares to the Selling Shareholder under the Purchase
Agreement, and the timing of any sales, will be determined by us from time to time in our sole discretion and will depend on a variety
of factors, including, among other things, market conditions, the trading price of our Depositary Shares and determinations by us regarding
the use of proceeds from any sale of such Depositary Shares. The net proceeds from any sales under the Committed Equity Financing will
depend on the frequency with, and prices at, which the Depositary Shares are sold to the Selling Shareholder. To the extent we sell shares
under the Purchase Agreement, we currently plan to use the net proceeds to fund our development programs, for working capital and other
general corporate purposes. We cannot predict whether the net proceeds invested will yield a favorable return.

In
accordance with our obligations under the Purchase Agreement and the Registration Rights Agreement, dated as of January 17, 2025, between
us and the Selling Shareholder, or the Registration Rights Agreement, pursuant to which we agreed to provide the Selling Shareholder
with customary registration rights related to the shares issued under the Purchase Agreement, we have filed a registration statement
of which this prospectus forms a part in order to register the resale of up to: (i) 35,000,000 Purchase Shares that we may elect, in
our sole discretion, to issue and sell to the Selling Shareholder, from time to time after the Commencement Date upon the terms and subject
to the conditions and limitations of the Purchase Agreement (assuming the shares are sold at a price of $1.00 per share); and (ii) 875,000
Commitment Shares that may be issued to the Selling Shareholder in certain circumstances in connection with related issuances and sales
of Purchase Shares to release the Company of its liability to pay the Commitment Fee as consideration for the Selling Shareholder’s
execution and delivery of the